Industry comments urge CMS to withdraw proposed rule mandating list price disclosures in TV ads, citing legal conflicts.
The US Centers for Medicare and Medicaid Services lacks the statutory authority to require manufacturers to disclose prescription drug prices in direct-to-consumer TV ads and is precluded from doing so by the First Amendment, manufacturers, free speech advocates and advertisers argue in recent comments to CMS.
The comments respond to a proposed rule on the price disclosure requirement released by CMS in mid-October. They detail anticipated...
The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.
The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
